x
ServiziMenu principaleHome
You are here: Home > Events > Future Events > 5th ESO-ESMO Latin-American Masterclass in Clinical Oncology
Print

Description

Chairs: A. Cervantes, ES - N. Pavlidis, GR - R.A. Stahel, CH
Scientific Co-ordinators: M. Aapro, CH - F. Cardoso, PT



FOREWORD
The Masterclass is the most structured ESO educational activity whose format has been established and presented in Europe for over a decade. The success of the teaching method has been confirmed by the events held also in other parts of the world as well as by the three editions held in Latin America. It is with pleasure and gratefulness for the consideration of the local community, that ESO announces the fifth edition to be held in the region in 2019.The Masterclass offers plenary lectures discussing current issues and controversies as well as critically reviewing significant therapeutic developments. State-of-the-art data recognized by ESMO and other evidence-based guidelines will be cited.
Participants will deliver case presentations within tumour boards and small groups and discuss them with the chairs and the faculty.
As for all Masterclasses, the number of participants will be limited and admission will be by competitive application only.
Admitted participants will be granted free registration and half-board accommodation for the duration of the Masterclass.

TEACHING FORMAT
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. The clinical sessions will be complemented by tumour board discussions supported by regional tutors.
Furthermore, participants will deliver case presentations within small groups and discuss these with the chairs and the faculty.
In preparation of the attendance, participants will be requested to follow four selected e-ESO sessions (www.e-eso.net).
All participants will reside at the course venue and participation is compulsory throughout the course.
The Masterclass will be entirely in English and at least an intermediate level of English is necessary for admission.

LEARNING OBJECTIVES
• Improve medical oncologists’ skills
• Practicing case discussion
• Deep focus on breast, gastro-intestinal, genitourinary, gynaecological, head and
neck and lung cancers
• Compact update on further topics of interest

MAIN TOPICS
• Breast cancer
• Gastro-intestinal cancers
• Genito-urinary cancers
• Gynaecological cancers
• Head and neck cancer
• Lung cancer

The Latin-American
Masterclass in
Clinical Oncology is an
ESO-ESMO joint event
         
Held in collaboration
with
         


                                                                                                                                                

Under the auspices of
         





     

 

 

Faculty

FACULTY (as November 2018)
M.S. Aapro, Clinique de Genolier, Genolier, CH
M.T. Bourlon, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MX
J.Y. Blay, Centre Léon Bérard, Lyon, FR
F. Calvo, Clinica Universidad de Navarra, Madrid, ES
F. Cardoso, Champalimaud Cancer Center, Lisbon, PT
L. Casanova Marquez, Clínica ALIADA, Lima, PE
F. Cavalli, Oncology Institute of Southern Switzerland, Bellinzona, CH
A. Cervantes, University Clinical Hospital, Valencia, ES
G. Curigliano, European Institute of Oncology, Milan, IT
E. Efstathiou, University of Texas MD Anderson Cancer Center, Houston, US
S.X. Franco, Clinical del Country, Bogota, CO
F. Geara, The American University of Beirut Medical Center, Beirut, LB
H. Gomez Moreno, Sociedad Peruana de Cancerologia, Lima, PE
J. Jeronimo, Global Coalition Against Cervical Cancer (GC3), Damascus, US
D. Lorusso, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
L. Mas Lopez, Instituto Nacional de Enfermedades Neoplásicas, Lima, PE
O. Michielin, Lausanne University Hospital – CHUV, Lausanne, CH
S. Neciosup, Instituto Nacional de Enfermedades Neoplasicas, Lima, PE
N. Pavlidis, University Hospital, Ioannina, GR
E. Payet, Instituto Nacional de Enfermedades Neoplásicas, Lima, PE
F.A. Peccatori, European School of Oncology and European Institute of Oncology, Milan, IT
F. Penault-Llorca, Centre Jean Perrin, Clermont-Ferrand, FR
C. Rolfo, University of Maryland School of Medicine, Baltimore, US
C. Santos, Instituto Nacional de Enfermedades Neoplásicas, Lima, PE
R.A. Stahel, University Hospital, Zurich, CH
R.M. Terra, University of São Paulo Medical School, São Paulo, BR
C. Vallejos, Oncosalud, Lima, PE
E. Van Cutsem, University Hospital Gasthuisberg, Leuven, BE
J.B. Vermorken, University Hospital Antwerp, Edegem, BE

General information

ORGANISING SECRETARIAT
European School of Oncology
Piazza Indipendeza 2, 6500 Bellinzona, Switzerland
Luis Carvalho, Ph: +41 91 820 09 58, E-mail: lcarvalho@eso.net

CME AND ESMO MORA ACCREDITATION AND CERTIFICATES
Participants will be entitled to receive a certificate of attendance at the close of the Masterclass by completing the online evaluation questionnaire.
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value.
The event is designated for a maximum of 33 European CME credits (ECMEC).
Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
Furthermore, the conference has been accredited with 25 ESMO-MORA category 1 points.

LANGUAGE
The Masterclass will be held in English and translation will not be provided.

INSURANCE
The organisers bear no responsibility for untoward events in relation to the participation in the event. Participants will be advised to take out their own personal and travel insurance coverage.

ACKNOWLEDGEMENTS
The Latin-American Masterclass in Clinical Oncology is funded by ESO and ESMO support with and unrestricted educational grants provided by Pfizer (Platinum sponsor), BMS (Gold sponsor), Lilly (Gold sponsor) and Roche (Gold sponsor) to whom ESO wishes to express its gratitude.

Application

PARTICIPANT’S PROFILE
• Age between 30 and 40 years
• At least 3 years’ experience in medical oncology (or clinical oncology)
• Involvement in scientific activities (desirable)
• Intermediate level of English language
• Practicing in Latin America

HOW TO APPLY
Interested oncologists should apply online (at the top of this page) prividing the following documents:
• Letter describing motivation for attending;
• Support letter from head of department or mentor;
• CV with list of publications (if the list is not provided, it will be assumed that no papers have been published);
• Clinical case abstract (see below).

Clinical case abstract
Applicants are requested to submit an abstract describing a clinical case related to one of the subjects of the Masterclass (breast, gastro-intestinal, genito-urinary, gynaecological, head and neck, and lung cancers).
It is suggested that, among the subjects of the Masterclass, the clinical case is on a tumour type that the applicant does not see frequently but that could add to the overall educational contents of the Masterclass. On the contrary, it is recommended that the case reflects the participant’s daily practice, avoiding uncommon or extremely rare cases which may have a lower educational impact.
The clinical case abstract should include diagnostic considerations, treatment, results and follow-up, at least three questions proposed for discussion.
Admitted participants will have the opportunity to present the clinical case in the format of a clinical grand round discussion to the chairs, tutors, other faculty members and participants.
The one-page abstract should be submitted on-line using the template available (at the bottom of this page), or by entering it in the application form.

The application outcome will be notified by e-mail by begin of February.

ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
Successful applicants are granted free registration and half-board accommodation

APPLICATION DEADLINE: 7 JANUARY 2019

Before you start completing the online application form, please be sure you have all the requested files (CV, Motivation letter, Supporting letter, Professional experience template and Abstract template) ready to be uploaded to the system. Online applications will not be complete unless all the files are uploaded.

TEMPLATES
Download HERE your Professional experience template
•  Download HERE your Abstract template

 

Programme

3 April

 13:00   Lunch
14:15   Welcome and introduction                  
14:25   Spotlight session The magnitude of the cancer problem in my country
H. Gomez Moreno, PE
    Discussion
14:55   Clinical session Genito-urinary cancers (I)   
Chair: E. Efstathiou, US
Prostate cancer:
    Active surveillance or watchful waiting
M. T. Bourlon, MX
    Local therapy: Surgery and radiotherapy   
F. Geara, LB
    First-line endocrine treatment  
E. Efstathiou, US
    Endocrine-resistant-refractory   
E. Efstathiou, US
    Discussion
17:15
  Coffee break 
17:30   Clinical session Genito-urinary cancers (II)   
Chair: to be confirmed
    Treatment of bladder cancer  
C. Vallejos, PE
   
Metastatic renal cancer: Evidence-based treatment  
Speaker to be confirmed
    Discussion
19:10   Tumour board Genito-urinary cancers
Participants’ case presentations  
C. Vallejos, PE
20:30
  Welcome dinner 

 

 4 April

8:00   Clinical session Breast cancer (I)   
Chair: G. Curigliano, IT
    What the clinician needs to know about breast pathology and sample quality  
F. Penault-Llorca, FR
    Genomic tests in clinical practice
F. Penault-Llorca, FR
    (Neo-) adjuvant chemotherapy and biological agents   
G. Curigliano, IT
    (Neo-) adjuvant endocrine therapy   
F. Cardoso, PT
    Discussion
10:05   Spotlight session The reality of clinical trials in Latin America
C. Rolfo, US 
    Discussion
 10:35   Coffee break   
10:55
  Clinical session Breast cancer (II)   
Chair: F. Cardoso, PT
    Recommended management of HER-2+ advanced breast cancer   
F. Cardoso, PT
    Recommended management for triple-negative advanced breast cancer   
G. Curigliano, IT
    Recommended management for ER+ advanced breast cancer   
S.X. Franco, CO
    ABC Global Alliance
F. Cardoso, PT
    Discussion
12:50
  Tumour board Breast cancer
Participants’ case presentations   
S.X. Franco, CO
13:50   Lunch
14:50   Spotlight session Melanoma (Videoconference)
O. Michielin , CH
    Discussion
15:25   Spotlight session Opportunities and limitations of liquid biopsies
F. Penault-Llorca, FR
    Discussion
16:00   Spotlight session Treatment of elderly patients
M. Aapro, CH
    Discussion
16:35   Coffee break
16:55   Spotlight session Management of cancer in young women
F. Cardoso, PT
    Discussion
17:30   Spotlight session Fertility preservation and pregnancy in cancer patients
F.A. Peccatori, IT
    Discussion
18:05   Spotlight session Management and treatment of toxicity
M. Aapro, CH
    Discussion
18:40   Spotlight session How do I get my work published in a peer-reviewed Journal
C. Rolfo, US
    Discussion

 

 5 April

8:30
  Clinical session Gynaecological cancers   
Chair: J.B. Vermorken, BE  
    New classification of gynaecological cancers
F. Penault Llorca, FR
    Ovarian cancer: Surgical and systemic treatment   
D. Lorusso, IT
    Cervical cancer: Primanry and secondary prevention   
J. Jeronimo, US 
    Cervical cancer: Systemic treatment    
D. Lorusso, IT
    Management of endometrial cancer  
J.B. Vermorken, BE
    Radiotherapy of gynaecological malignancies   
F. Geara, LB
    Discussion
11:20   Coffee break   
11:40   Tumour board Gynaecological cancers   
Participants’ case presentations
C. Santos, PE
12:10
  Spotlight session Cancer of unknown primary  
N. Pavlidis, GR
    Discussion
12:50   Lunch 
14:00   Clinical session Head and neck cancer   
Chair: J.B. Vermorken, BE
    When to operate?
Speaker to be confirmed
    When to irradiate?
F. Calvo, ES
    Systemic therapy and radio-chemotherapy
J.B. Vermorken, BE
    Discussion
16:05   Tumour board Head and neck cancer   
Participants’ case presentations
Tutor to be confirmed      
16:40
  Coffee break 
17:00
  Group sessions (four/five groups)   
Tutors: L. Casanova Marquez, PE - L. Mas Lopez, PE - S. Neciosup, PE
Part I: Clinical case presentations by participants
Part II: Selected participants present their national situation ("How is cancer treated in my country")

 

 6 April

  8:30   Clinical session Gastro-intestinal tumours (I)   
Chair: A. Cervantes, ES
    Adjuvant and neo-adjuvant treatment of colorectal cancer   
E. Van Cutsem, BE
    Systemic treatment in advanced disease (including liver)   
E. Van Cutsem, BE
    Discussion
9:50
  Coffee break   
10:10
  Clinical session Gastro-intestinal tumours (II)   
Chair: E. Van Cutsem, BE
    Management of early rectal cancer: Any role for adjuvant chemotherapy?   
A. Cervantes, ES
    Systemic treatment in early and advanced gastric cancers and esophageal cancer   
A. Cervantes, ES
    Pancreatic and biliary tract cancers   
E. Van Cutsem, BE
    Discussion
12:10   Tumour board Gastro-intestinal tumours  
Participants’ case presentations
E. Payet, PE
 13:10   Lunch
14:10
  Spotlight session Sarcoma and GIST
J.Y. Blay, FR (videoconfonference)
    Discussion
15:05   Spotlight session Has immunotherapy kept its promises in malignant lymphomas
F. Cavalli, CH (videoconfonference)
    Discussion
 15:45   Spotlight session ESMO guidance on evaluation of treatment benefit
R.A. Stahel, CH
16:25   Coffee break  
16:45   Group sessions  
Tutors: L. Casanova Marquez, PE - L. Mas Lopez, PE - S. Neciosup, PE
Part I: Clinical case presentations by participants
Part II: Selected participants present their national situation ("How is cancer treated in my country")
 19:15   Sponsored lecture (19:15-19:45)
20:30
  Farewell dinner   

 

 7 April

 8:30   Clinical session Lung cancer (I)   
Chair: R.A. Stahel, CH  
    Molecular classification of lung cancer for clinical practice
F. Penault-Llorca, FR
    Surgery   
R.M Terra, BR
    Radiotherapy   
F. Calvo, ES
    Non-small cell lung cancer systemic therapy   
R.A. Stahel, CH
    Discussion
11:00   Coffee break 
11:20   Clinical session Lung cancer (II)  
Chair: R.A. Stahel, CH
    Small cell lung cancer   
R.A. Stahel, CH
    Discussion
11:55
  Tumour board Lung cancer  
Participants’ case presentations
Faculty and Tutor: R.M. Terra, BR
12:55
  Learning assessment test   
13:40
-14:40
  Lunch followed by departures  

 

 

 

Follow us